JP2015530973A5 - - Google Patents

Download PDF

Info

Publication number
JP2015530973A5
JP2015530973A5 JP2015523156A JP2015523156A JP2015530973A5 JP 2015530973 A5 JP2015530973 A5 JP 2015530973A5 JP 2015523156 A JP2015523156 A JP 2015523156A JP 2015523156 A JP2015523156 A JP 2015523156A JP 2015530973 A5 JP2015530973 A5 JP 2015530973A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
acid sequence
seq
antibody according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015523156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015530973A (ja
JP6578206B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/050489 external-priority patent/WO2014014821A1/en
Publication of JP2015530973A publication Critical patent/JP2015530973A/ja
Publication of JP2015530973A5 publication Critical patent/JP2015530973A5/ja
Application granted granted Critical
Publication of JP6578206B2 publication Critical patent/JP6578206B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015523156A 2012-07-19 2013-07-15 Cd22に特異的な抗体およびその使用方法 Active JP6578206B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261673630P 2012-07-19 2012-07-19
US61/673,630 2012-07-19
PCT/US2013/050489 WO2014014821A1 (en) 2012-07-19 2013-07-15 Antibody specific for cd22 and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019093305A Division JP2019150052A (ja) 2012-07-19 2019-05-17 Cd22に特異的な抗体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2015530973A JP2015530973A (ja) 2015-10-29
JP2015530973A5 true JP2015530973A5 (cg-RX-API-DMAC7.html) 2016-09-01
JP6578206B2 JP6578206B2 (ja) 2019-09-18

Family

ID=49949191

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015523156A Active JP6578206B2 (ja) 2012-07-19 2013-07-15 Cd22に特異的な抗体およびその使用方法
JP2019093305A Withdrawn JP2019150052A (ja) 2012-07-19 2019-05-17 Cd22に特異的な抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019093305A Withdrawn JP2019150052A (ja) 2012-07-19 2019-05-17 Cd22に特異的な抗体およびその使用方法

Country Status (10)

Country Link
US (4) US9181343B2 (cg-RX-API-DMAC7.html)
EP (2) EP3539563A1 (cg-RX-API-DMAC7.html)
JP (2) JP6578206B2 (cg-RX-API-DMAC7.html)
KR (1) KR102165464B1 (cg-RX-API-DMAC7.html)
CN (1) CN104582717B (cg-RX-API-DMAC7.html)
AU (1) AU2013290424B2 (cg-RX-API-DMAC7.html)
CA (1) CA2878642C (cg-RX-API-DMAC7.html)
IN (1) IN2015DN00552A (cg-RX-API-DMAC7.html)
RU (1) RU2015105588A (cg-RX-API-DMAC7.html)
WO (1) WO2014014821A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015105588A (ru) * 2012-07-19 2016-09-10 Редвуд Байосайнс, Инк. Антитело, специфическое к cd22, и способы его применения
EP3110445A4 (en) * 2014-02-25 2017-09-27 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
SG11201608772UA (en) 2014-04-27 2016-11-29 Ccam Biotherapeutics Ltd Humanized antibodies against ceacam1
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
JP6855496B2 (ja) 2015-11-09 2021-04-07 アール.ピー.シェーラー テクノロジーズ エルエルシー 抗cd22抗体−メイタンシンコンジュゲートおよびその使用方法
BR112019021520A2 (pt) 2017-04-14 2020-08-04 Tollnine, Inc. oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
JP2020534352A (ja) * 2017-09-07 2020-11-26 キュー バイオファーマ,インコーポレーテッド コンジュゲーション部位を有するt細胞調節多量体ポリペプチド及びその使用方法
IL295413A (en) * 2020-02-27 2022-10-01 Phanes Therapeutics Inc Antibodies conjugated with fatty acid molecules and their uses
MX2022010515A (es) * 2020-02-28 2022-11-14 Tallac Therapeutics Inc Conjugacion mediada por transglutaminasa.
CN115667310A (zh) * 2020-06-01 2023-01-31 创新生物有限公司 Cd22特异性抗体及其用途
CN115210262B (zh) * 2020-09-29 2023-07-14 昆明赛诺制药股份有限公司 人源化抗-cd22重组免疫毒素及其应用
KR20220122844A (ko) * 2021-02-26 2022-09-05 (주)이노베이션바이오 Cd22에 특이적인 인간화 항체 및 이의 용도
AU2022369457A1 (en) * 2021-10-18 2024-05-02 Sinomab Bioscience Limited Aqueous formulations of an anti-cd22 antibody and uses thereof
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
TW197439B (cg-RX-API-DMAC7.html) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
ES2197145T3 (es) 1991-08-20 2004-01-01 The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services Transferencia de genes mediada por adenovirus al gastrointestinal.
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
AU3140093A (en) 1991-11-22 1993-06-15 University Of Mississippi, The Synthesis and optical resolution of the taxol side chain and related compounds
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH08500973A (ja) 1992-05-21 1996-02-06 ザ ペン ステイト リサーチ ファウンデーション タキソール、関連タキサン及び他の新規な抗癌/抗ウイルス性化合物原料としてのイチイ培養組織
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
US5484892A (en) 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
HU223733B1 (hu) 1993-10-25 2004-12-28 Canji, Inc. Rekombináns adenovírus vektor és eljárás alkalmazására
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
WO1996004925A1 (en) 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
ES2178101T3 (es) 1994-12-09 2002-12-16 Imp College Innovations Ltd Genes de virulencia en la region vgc2 de salmonella.
WO1996019487A1 (en) 1994-12-22 1996-06-27 Nissan Chemical Industries, Ltd. Organobismuth derivatives and process for producing the same
US5958713A (en) 1995-01-31 1999-09-28 Novo Nordisk A/S Method of detecting biologically active substances by using green fluorescent protein
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
EP0831100B1 (en) 1995-04-21 2000-10-11 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivatives
ATE247488T1 (de) 1995-10-13 2003-09-15 Us Gov Health & Human Serv Immunotoxin enthaltend ein disulfid- stabilisiertes antikörperfragment
US5968738A (en) 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
US6020192A (en) 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
WO1997034632A1 (en) 1996-03-20 1997-09-25 Immunomedics, Inc. Glycosylated humanized b-cell specific antibodies
WO1998008833A1 (en) 1996-08-26 1998-03-05 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
DE69708318T3 (de) 1996-08-27 2006-11-16 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
EP0961619A4 (en) 1996-09-27 2001-09-26 Bristol Myers Squibb Co HYDROLYSABLE DRUGS FOR THE RELEASE OF ANTI-CANCER DRUGS IN METASTATIC CELLS
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
TW371617B (en) 1996-10-09 1999-10-11 Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV
US6395276B1 (en) 1997-05-02 2002-05-28 Immunomedics, Inc. Immunotoxins directed against malignant cells
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
WO1998022451A1 (en) 1996-11-19 1998-05-28 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
AU740904B2 (en) * 1997-03-20 2001-11-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
GB9712892D0 (en) 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
IL133585A0 (en) 1997-06-20 2001-04-30 Baker Norton Pharma Soluble prodrugs of paclitaxel
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
DE69729128T2 (de) 1997-10-08 2005-04-28 Bio Research Corporation Of Yokohama, Yokohama Taxoid-derivate und verfahren zu ihrer herstellung
CA2313225A1 (en) 1997-12-12 1999-06-17 Macromed, Inc. Heterofunctionalized star-shaped poly(ethylene glycols) for protein modification
US5985577A (en) 1998-10-14 1999-11-16 The Trustees Of Columbia University In The City Of New York Protein conjugates containing multimers of green fluorescent protein
DE60042785D1 (de) 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
ES2344592T3 (es) 2001-01-05 2010-09-01 Pfizer Inc. Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i.
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
WO2003027135A2 (en) 2001-09-26 2003-04-03 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
EP1476120B1 (en) 2002-02-21 2010-09-29 Duke University Treatment methods using anti-cd22 antibodies
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
US7456260B2 (en) 2002-06-17 2008-11-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Humanized antibody
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
CA2568952C (en) 2004-06-18 2019-05-21 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
US7255012B2 (en) 2004-12-01 2007-08-14 Rosemount Inc. Process fluid flow device with variable orifice
DK1844074T3 (da) 2005-02-03 2013-07-15 Antitope Ltd Humane antistoffer og proteiner
EP2395026B1 (en) * 2005-02-08 2018-01-24 The Chemo-Sero-Therapeutic Research Institute Method for improving antibody
AU2007223903B2 (en) 2006-03-06 2013-09-05 Medimmune, Llc Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
NZ597251A (en) 2006-05-30 2013-08-30 Genentech Inc Antibodies and immunoconjugates and uses therefor
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
KR101552735B1 (ko) * 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
WO2010096394A2 (en) * 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
CN102666582B (zh) * 2009-12-22 2016-03-30 弗·哈夫曼-拉罗切有限公司 序列依赖性聚集
AR083495A1 (es) * 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
RU2015105588A (ru) * 2012-07-19 2016-09-10 Редвуд Байосайнс, Инк. Антитело, специфическое к cd22, и способы его применения

Similar Documents

Publication Publication Date Title
JP2015530973A5 (cg-RX-API-DMAC7.html)
RU2015105588A (ru) Антитело, специфическое к cd22, и способы его применения
HRP20210739T1 (hr) Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada
Rothbard et al. Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells
JP2018502060A5 (cg-RX-API-DMAC7.html)
JP2018064568A5 (cg-RX-API-DMAC7.html)
JP2014039548A5 (cg-RX-API-DMAC7.html)
RU2017134140A (ru) Конструкции, направленные на комплексы пептида аfp/мнс, и виды их использования
HRP20202024T1 (hr) Cd3-vežuća domena
HRP20180937T1 (hr) Poboljšavanje transporta terapijskih molekula kroz krvno-moždanu barijeru
JP2018512145A5 (cg-RX-API-DMAC7.html)
JP2010533498A5 (cg-RX-API-DMAC7.html)
IL275497B (en) Serum proteins with type iii fibronectin binding domains
JP2018520092A5 (cg-RX-API-DMAC7.html)
HRP20240719T1 (hr) Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba
RU2017142716A (ru) Конструкции, направленные на комплексы пептида hpv16-e7/мнс, и виды их использования
EP4434543A3 (en) Human igg1 fc region variants and uses thereof
JP2017529067A5 (cg-RX-API-DMAC7.html)
JP2019510733A5 (cg-RX-API-DMAC7.html)
SI2530091T1 (en) PROTITELO ANTI-DLL3
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
WO2012040323A8 (en) Multimeric il-15 soluble fusion molecules and methods of making and using same
JP2016502515A5 (cg-RX-API-DMAC7.html)
EA201391159A1 (ru) Hla-рестриктированные пептидоспецифические антигенсвязывающие белки
EP3970746A3 (en) Polypeptide variants and uses thereof